I
Irbaz Bin Riaz
Researcher at Mayo Clinic
Publications - 179
Citations - 3356
Irbaz Bin Riaz is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 123 publications receiving 2028 citations. Previous affiliations of Irbaz Bin Riaz include Harvard University & University of Kansas.
Papers
More filters
Journal ArticleDOI
Drug treatments for covid-19: living systematic review and network meta-analysis.
Reed A C Siemieniuk,Jessica J Bartoszko,Long Ge,Dena Zeraatkar,Ariel Izcovich,Elena Kum,Hector Pardo-Hernandez,Anila Qasim,Juan Pablo Diaz Martinez,Bram Rochwerg,Francois Lamontagne,Mi Ah Han,Qin Liu,Arnav Agarwal,Arnav Agarwal,Thomas Agoritsas,Derek K. Chu,Rachel Couban,Ellen Cusano,Andrea Darzi,Tahira Devji,Bo Fang,Carmen Fang,Signe Flottorp,Signe Flottorp,Farid Foroutan,Farid Foroutan,Maryam Ghadimi,Diane Heels-Ansdell,Kimia Honarmand,Liangying Hou,Xiaorong Hou,Quazi Ibrahim,Assem M. Khamis,Bonnie Lam,Mark Loeb,Maura Marcucci,Shelley McLeod,Sharhzad Motaghi,Srinivas Murthy,Reem A. Mustafa,Reem A. Mustafa,John Neary,Gabriel Rada,Irbaz Bin Riaz,Behnam Sadeghirad,Nigar Sekercioglu,Lulu Sheng,Ashwini Sreekanta,Charlotte Switzer,Britta Tendal,Lehana Thabane,George Tomlinson,Tari Turner,Per Olav Vandvik,Robin W.M. Vernooij,Andrés Viteri-García,Ying Wang,Liang Yao,Zhikang Ye,Gordon H Guyatt,Romina Brignardello-Petersen +61 more
TL;DR: Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.
Journal ArticleDOI
Survival Benefit of Solid-Organ Transplant in the United States
Abbas Rana,Angelika C. Gruessner,Vatche G. Agopian,Zain Khalpey,Irbaz Bin Riaz,Bruce Kaplan,Karim J. Halazun,Ronald W. Busuttil,Rainer W.G. Gruessner +8 more
TL;DR: It is demonstrated that more than 2 million life-years were saved to date by solid-organ transplants during a 25-year study period.
Journal ArticleDOI
Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
Atlantis Dawn Russ,Anh Hua,William R. Montfort,Bushra Rahman,Irbaz Bin Riaz,Muhammad Umar Khalid,Jennifer S. Carew,Steffan T. Nawrocki,Daniel O. Persky,Faiz Anwer +9 more
TL;DR: A large body of preclinical evidence and emerging clinical data supporting the use of antibodies designed to target the CD47-SIRPα interaction in leukemia, lymphoma and multiple myeloma are summarized.
Journal ArticleDOI
Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map
Safi U. Khan,Muhammad U. Khan,Haris Riaz,Shahul Valavoor,Di Zhao,Lauren Vaughan,Victor Okunrintemi,Irbaz Bin Riaz,Muhammad Shahzeb Khan,Edo Kaluski,M. Hassan Murad,Michael J. Blaha,Eliseo Guallar,Erin D. Michos +13 more
TL;DR: A systematic review of existing meta-analyses of RCTs and generated an evidence map for efficacy of nutritional supplements and dietary interventions for CVD prevention, using PubMed, CINAHL, and the Cochrane Library as sources.
Journal ArticleDOI
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis
Mohamad Bassam Sonbol,Irbaz Bin Riaz,Syed Arsalan Ahmed Naqvi,Daniel R. Almquist,Syeda A. Mina,Jehad Almasri,Shiv Shah,Diana Almader-Douglas,Pedro Luiz Serrano Uson Junior,Amit Mahipal,Wen Wee,Zhaohui Jin,Kabir Mody,Jason S. Starr,Mitesh J. Borad,Daniel H. Ahn,M. Hassan Murad,Tanios Bekaii-Saab +17 more
TL;DR: This systematic review and NMA of 14 trials found that atezolizumab and bevacizumAB in combination is now considered the standard of care in the first-line setting in patients with advanced HCC, and regorafenib and cabozantinib are preferred options in refractory patients.